Valuation: Allogene Therapeutics, Inc.

Market Cap 504M 451M 420M 382M 719M 48.79B 725M 5.05B 1.97B 24.82B 1.89B 1.85B 79.78B P/E 2026 *
-2.42x
P/E 2027 * -2.27x
Enterprise Value 308M 275M 257M 233M 439M 29.78B 442M 3.08B 1.2B 15.15B 1.16B 1.13B 48.69B EV / Sales 2026 *
90.6x
EV / Sales 2027 * 29.3x
Free-Float
88.97%
Yield 2026 *
-
Yield 2027 * -
Sep. 14 Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company MT
Sep. 09 Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:00 AM
Sep. 02 Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026 CI
Sep. 02 Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Executive Vice President and Principal Financial Officer, Effective November 6, 2026 CI
Sep. 02 Allogene Therapeutics CFO Geoffrey Parker to Retire MT
Aug. 13 Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says MT
Aug. 12 Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
Aug. 12 Allogene Therapeutics Q2 Loss Narrows MT
Aug. 12 Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss MT
Aug. 12 Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 12 Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL CI
Jul. 29 Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations MT
Jul. 29 Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma CI
1 day-1.03%
1 week-10.31%
Current month-10.31%
1 month-22.85%
3 months-33.26%
6 months-45.23%
Current year+4.74%
1 week 1.42
Extreme 1.425
1.61
1 month 1.42
Extreme 1.425
1.94
Current year 1.31
Extreme 1.31
4.46
1 year 1.04
Extreme 1.04
4.46
3 years 0.86
Extreme 0.8621
5.78
5 years 0.86
Extreme 0.8621
20.75
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 2026-06-30
Director of Finance/CFO 61 2023-10-15
Chief Tech/Sci/R&D Officer 49 2025-02-27
Director TitleAgeSince
Chairman 76 2017-10-31
Director/Board Member 66 2018-05-31
Director/Board Member 49 2017-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Sell

Compliance Officer

-29,697 0.0086%
7/1/26 Free

Chief Executive Officer

610,720 0.1769%
6/18/26 Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%-10.31%+6.30%-51.68% 504M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.57% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
-0.29%-2.56%+329.49%+685.30% 42.84B
-0.53%-3.67%+28.93%+29.78% 42.79B
+0.32%-0.50%+6.59%+110.73% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
+0.46%-2.33%-9.48%-12.17% 24.05B
Average +0.12%-1.22%+48.57%+104.92% 39.48B
Weighted average by Cap. +0.64%-0.55%+56.10%+128.43%

Financials

2026 *2027 *
Net sales 3.4M 3.04M 2.83M 2.57M 4.85M 329M 4.88M 34.06M 13.31M 167M 12.76M 12.49M 538M 12.09M 10.8M 10.07M 9.15M 17.23M 1.17B 17.36M 121M 47.3M 595M 45.37M 44.39M 1.91B
Net income -185M -165M -154M -140M -264M -17.91B -266M -1.85B -725M -9.11B -695M -680M -29.28B -220M -196M -183M -166M -313M -21.27B -316M -2.2B -860M -10.82B -825M -807M -34.77B
Net Debt -197M -176M -164M -149M -280M -19.01B -282M -1.97B -769M -9.67B -738M -722M -31.08B -150M -134M -125M -114M -214M -14.53B -216M -1.5B -588M -7.39B -564M -552M -23.75B
Projected Income Statement - Annual - Allogene Therapeutics, Inc.
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
26-10-07 $1.430 -2.05% 3,886,309
26-10-06 $1.460 -2.67% 4,659,678
26-10-05 $1.500 0.00% 4,443,265
26-10-02 $1.500 -2.60% 4,656,621
26-10-01 $1.540 -3.75% 4,606,898
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Allogene Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1.460USD
Average target price
9.000USD
Spread / Average Target
+516.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Allogene Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ALLO Stock